The OncoAssure Process
OncoAssure aims to meet the most critical clinical needs by combining the latest transcriptomic and mathematical modelling techniques followed by stringent analytical and clinical validation.
The “Master Driver” Genes
The central principle of the OncoAssure process is to identify a concise panel of upstream “master driver” genes which represent a reliable indicator of disease progression, rather than a long list of “passenger” genes. The two key components of the “master driver” genes are that they regulate the expression of other prognostic genes and they provide significant prognostic information beyond that provided by standard clinical and pathological information.
Once the “master driver” genes for predicting disease progression are identified, OncoAssure uses its tested and proven bioinformatic process to develop and manufacture highly sensitive and reproducible RT-qPCR-based in vitro diagnostic (IVD) assays.
Optimised and validated workflow
At OncoAssure we believe clinicians and patients benefit from easy access to fast and reliable diagnostic tests for timely clinical decisions. The OncoAssure IVDs are designed to be run at local hospital laboratories on standard RT-qPCR instruments with fully validated test reagents.
